Drug off-target is a key parameter for evaluating drug safety. Off-target will lead to unpredictable clinical toxicity, affecting clinical trials and new drug application. Off-target studies of monoclonal drugs have traditionally been carried out through tissue cross-reactivity confirmation, but false positives often occur, so a more sensitive and accurate method is needed to explore the targeted safety of drugs. The Membrance Proteofetch Array technology is to forms a cell array by expressing membrane proteins on living cells, performs specificity assessment for drugs, has identified specific targeting segments, and provides detailed specificity information for drug development and new drug submission.
